We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Selumetinib Fails in Eye Cancer Trial
AstraZeneca’s Selumetinib Fails in Eye Cancer Trial
AstraZeneca’s investigational drug selumetinib has failed to meet its primary endpoint of progression free survival during a Phase 3 trial for a rare eye cancer.